Cardlytics (NASDAQ:CDLX) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Cardlytics (NASDAQ:CDLX) from a hold rating to a sell rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

Several other research analysts also recently commented on CDLX. Weiss Ratings reissued a “sell (e+)” rating on shares of Cardlytics in a research note on Wednesday, July 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cardlytics in a report on Thursday, June 18th. One investment analyst has rated the stock with a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Cardlytics presently has an average rating of “Sell” and an average price target of $10.00.

Cardlytics Stock Down 3.6%

CDLX opened at $3.75 on Friday. Cardlytics has a twelve month low of $3.49 and a twelve month high of $32.80. The company has a 50-day moving average price of $3.98 and a 200 day moving average price of $6.19. The company has a market cap of $21.79 million, a PE ratio of -0.20 and a beta of 0.67.

Cardlytics (NASDAQ:CDLX) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.30) by $0.80. Cardlytics had a negative return on equity of 956.56% and a negative net margin of 55.92%.The company had revenue of $36.88 million for the quarter, compared to analysts’ expectations of $37.00 million. As a group, sell-side analysts expect that Cardlytics will post -3.89 earnings per share for the current year.

Insiders Place Their Bets

In other Cardlytics news, CEO Amit Gupta sold 9,640 shares of the firm’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $4.39, for a total transaction of $42,319.60. Following the completion of the sale, the chief executive officer owned 113,850 shares of the company’s stock, valued at $499,801.50. This trade represents a 7.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 31,750 shares of company stock valued at $134,129 in the last ninety days. Corporate insiders own 5.90% of the company’s stock.

Hedge Funds Weigh In On Cardlytics

A hedge fund recently bought a new stake in Cardlytics stock. Worldly Partners Management LLC acquired a new stake in Cardlytics, Inc. (NASDAQ:CDLX) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 115,798 shares of the company’s stock, valued at approximately $520,000. Cardlytics accounts for about 0.4% of Worldly Partners Management LLC’s holdings, making the stock its 3rd largest position. Worldly Partners Management LLC owned approximately 1.99% of Cardlytics at the end of the most recent quarter. 68.10% of the stock is currently owned by institutional investors and hedge funds.

Cardlytics Company Profile

Cardlytics, Inc is an advertising technology company that connects marketers with consumers through financial institutions. Its platform uses transaction-based insights to help advertisers reach customers with relevant offers and measure the impact of advertising on consumer spending.

Cardlytics’ services are integrated into banking and financial applications, where consumers may receive personalized cash-back offers, discounts and other promotions based on their shopping activity. Participating financial institutions can use the platform to provide additional value to customers while generating advertising revenue.

The company serves advertisers across categories such as retail, dining, travel and financial services, and works with banks and other financial institutions primarily in the United States and the United Kingdom.